Giant obscurins regulate the PI3K cascade in breast epithelial cells via direct binding to the PI3K/p85 regulatory

Marey Shriver1, Saravanakumar Marimuthu1, Colin Paul2,3,4

  • 1Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.

Oncotarget
|June 22, 2016
PubMed

Insights

Giant obscurins suppress breast cancer progression by inhibiting the PI3K pathway. Loss of these proteins activates PI3K signaling, promoting tumor growth and metastasis.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Cancer Research

Background:

  • Obscurins are giant cytoskeletal proteins with known roles in muscle tissue.
  • Obscurins are expressed in normal breast cells, suppressing tumors and metastasis.
  • Loss of obscurins correlates with advanced breast cancer and promotes tumor progression.

Purpose of the Study:

  • To investigate the mechanism by which obscurins suppress breast cancer progression.
  • To determine the role of obscurins in regulating the PI3K signaling pathway.
  • To elucidate the interaction between obscurins and PI3K components.

Main Methods:

  • Analysis of obscurin expression in breast cancer biopsies.
  • In vitro and in vivo studies on obscurin-depleted breast epithelial cells.
  • Pharmacological and molecular inhibition of the PI3K pathway.
  • Biochemical assays including co-immunoprecipitation, pull-down, and surface plasmon resonance.

Main Results:

  • Loss of obscurins in breast cells significantly increases PI3K/AKT pathway activation.
  • Inhibition of the PI3K pathway reverses EMT, restores cell junctions, and reduces migration/invasion in obscurin-depleted cells.
  • Obscurins directly bind to the PI3K/p85 regulatory subunit via specific protein domains.

Conclusions:

  • Giant obscurins act upstream of the PI3K cascade in normal breast epithelial cells.
  • Obscurins regulate PI3K activation through direct physical interaction with PI3K/p85.
  • Restoring obscurin function could be a therapeutic strategy against breast cancer metastasis.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.7K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.8K